natgillin/translations-raw huggingface dataset:
VELCADE 3.5 mg reconstituted solution is administered as a 3-5 second bolus intravenous injection through a peripheral or central intravenous catheter followed by a flush with sodium chloride 9 mg/ml (0.9%) solution for injection.
Pripremljena otopina VELCADEa od 3,5 mg se primjenjuje intravenskom bolus injekcijom u trajanju od 3-5 sekundi kroz periferni ili centralni venski kateter, koji se potom mora isprati 9 mg/ml (0,9%) otopinom za injekciju natrijevog klorida.
VELCADE 3.5 mg reconstituted solution is administered subcutaneously through the thighs (right or left) or abdomen (right or left).
Pripremljena otopina VELCADEa od 3,5 mg se primjenjuje supkutano u bedro (desno ili lijevo) ili abdomen (desnu ili lijevu stranu).
VELCADE combination treatment with dexamethasone
Kombinirano liječenje VELCADEom s deksametazonom
VELCADE contains the active substance bortezomib, a so-called ‘proteasome inhibitor’.
VELCADE sadrži djelatnu tvar bortezomib, koja se naziva ‘inhibitor proteasoma’.
VELCADE dose should be reduced by 1 dose level (from 1.3 mg/m2 to 1 mg/m2, or from
Doza VELCADEa mora se smanjiti za jednu razinu doze (s 1,3 mg/m2 na 1 mg/m2, ili s
VELCADE in combination with dexamethasone) and patients in the comparison group (e.g.
VELCADE u kombinaciji s deksametazonom) i bolesnici u usporednoj skupini (npr.
VELCADE is given intravenously on days 1, 4, 8 and 11, followed by a ‘rest period’ without treatment.
VELCADE se primjenjuje u venu 1., 4., 8. i 11. dan, nakon čega slijedi ‘period odmora’ bez liječenja.
VELCADE is given intravenously or subcutaneously on days 1, 4, 8 and 11, followed by a ‘rest period’ without treatment.
VELCADE se primjenjuje u venu ili potkožno 1., 4., 8. i 11. dan, nakon čega slijedi ‘period odmora’ bez liječenja.
VELCADE is used for the treatment of multiple myeloma (a cancer of the bone marrow) in patients older than 18 years:
VELCADE se primjenjuje u liječenju bolesnika s multiplim mijelomom (rak koštane srži) u bolesnika starijih od 18 godina:
VELCADE must be reconstituted by a healthcare professional.
VELCADE mora rekonstituirati zdravstveni djelatnik.
VELCADE powder for solution for injection is a white to off-white cake or powder.
VELCADE prašak za otopinu za injekciju je bijeli do gotovo bijeli kolačić ili prašak.
VELCADE should not be administered intrathecally.
VELCADE se ne smije primjeniti intratekalno.
VELCADE should not be used during pregnancy unless the clinical condition of the woman requires treatment with VELCADE.
VELCADE se ne smije primjenjivati tijekom trudnoće, osim ako kliničko stanje žene ne zahtijeva liječenje VELCADEom.
VELCADE therapy should be withheld
Liječenje VELCADEom mora se prekinuti
VELCADE therapy should be withheld
VELCADE se mora prekinuti
VELCADE therapy should be withheld until symptoms of the toxicity have resolved to Grade 1 or baseline.
Liječenje VELCADEom mora se prekinuti dok se simptomi toksičnosti ne povuku na 1. stupnja ili početnu težinu.
VELCADE therapy should be withheld until symptoms of the toxicity have resolved to Grade 2 or better.
Liječenje VELCADEom mora se prekinuti dok se simptomi toksičnosti ne povuku do stupnja 2 ili manjeg.
VELCADE therapy should be withheld when the platelet count is < 25,000/l or, in the case of combination with melphalan and prednisone, when the platelet count is ≤ 30,000/l (see section 4.2).
Liječenje VELCADEom mora se prekinuti kad je broj trombocita < 25 000/l, a u slučaju kombinacije s melfalanom i prednizonom kad je broj trombocita ≤ 30 000/l (vidjeti dio 4.2).
VELCADE treatment is commonly associated with orthostatic/postural hypotension.
Liječenje VELCADEom često je povezano s ortostatskom/posturalnom hipotenzijom.
VELCADE treatment is very commonly associated with haematological toxicities (thrombocytopenia, neutropenia and anaemia).
Liječenje VELCADEom vrlo je često povezano s hematološkim toksičnostima (trombocitopenija, neutropenija i anemija).
VELCADE treatment must be withheld at the onset of any Grade 3 non-haematological or any Grade 4 haematological toxicities, excluding neuropathy as discussed below (see also section 4.4).
Liječenje VELCADEom mora se prekinuti po javljanju svake nehematološke toksičnosti 3. stupnja ili bilo kakve hematološke toksičnosti 4. stupnja, isključujući neuropatiju, kako je objašnjeno u daljnjem tekstu (vidjeti također dio 4.4).
VELCADE will be administered by a health care professional experienced in the use of cytotoxic medicines.
VELCADE će Vam primijeniti liječnik koji ima iskustvo u primjeni citotoksičnih lijekova.
VELCADE) are made comparable with respect to confounding factors by individually pairing study subjects.
VELCADE) učine usporedivima s obzirom na zbunjujuće čimbenike, tako da se indivdualno uparuju ispitanici u ispitivanju.
Velmetia contains two different medicines called sitagliptin and metformin. sitagliptin belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) metformin belongs to a class of medicines called biguanides.
Velmetia sadrži dva različita lijeka koji se zovu sitagliptin i metformin. sitagliptin pripada skupini lijekova koji se zovu DPP-4 inhibitori (inhibitori dipeptidil peptidaze-4). metformin pripada skupini lijekova koji se zovu bigvanidi.
Velmetia is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
Lijek Velmetia je također indiciran kao dodatak inzulinu (tj. kao dio trojne kombinirane terapije), a kao dopuna dijeti i tjelovježbi, za poboljšanje regulacije glikemije u bolesnika u kojih stabilna doza inzulina i samo metformin ne omogućavaju odgovarajuću regulaciju glikemije.
Velmetia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.
Lijek Velmetia je indiciran kao dopuna dijeti i tjelovježbi za poboljšanje regulacije glikemije u bolesnika u kojih ista nije odgovarajuće regulirana primjenom najviše podnošljive doze samo metformina ili u onih koji se već liječe kombinacijom sitagliptina i metformina.
Velmetia is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPAR) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.
Lijek Velmetia je indiciran kao dio trojne kombinirane terapije s agonistom receptora za aktivator proliferacije peroksisoma-gama (engl. peroxisome proliferator-activated receptor gamma, PPAR) (tj. tiazolidindionom) kao dopuna dijeti i tjelovježbi u bolesnika koji nisu odgovarajuće regulirani primjenom najviše podnošljive doze metformina i agonista PPAR.
Velmetia is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
Lijek Velmetia je indiciran u kombinaciji sa sulfonilurejom (tj. kao dio trojne kombinirane terapije) kao dopuna dijeti i tjelovježbi u bolesnika koji nisu odgovarajuće regulirani primjenom najviše podnošljive doze metformina i sulfonilureje.
Velmetia must not be used in patients with hepatic impairment (see sections 4.3 and 5.2).
Velmetia se ne smije primjenjivati u bolesnika s oštećenjem funkcije jetre (vidjeti dijelove 4.3 i 5.2).
Velmetia must therefore not be used in women who are breast-feeding (see section 4.3).
Stoga dojilje ne smiju uzimati lijek Velmetia (vidjeti dio 4.3).
Velmetia should not be used in patients with moderate or severe renal impairment (creatinine clearance < 60 mL/min) (see sections 4.3 and 4.4).
Velmetia se ne smije primjenjivati u bolesnika s umjerenim ili teškim oštećenjem funkcije bubrega (klirens kreatinina < 60 ml/min) (vidjeti dijelove 4.3 i 4.4).
Velmetia should not be used in patients with type 1 diabetes and must not be used for the treatment of diabetic ketoacidosis.
Lijek Velmetia se ne smije primjenjivati u bolesnika s dijabetesom tipa 1 ili za liječenje dijabetičke ketoacidoze.
Velpatasvir
ANTIMIKOBAKTERICI
Velpatasvir is > 99.5% bound to human plasma proteins and binding is independent of drug concentration over the range of 0.09 μg/mL to 1.8 μg/mL.
Velpatasvir je > 99,5 % vezan za proteine ljudske plazme i vezanje ne ovisi o koncentraciji lijeka u rasponu od 0,09 μg/ml do 1,8 μg/ml.
Velpatasvir is a HCV inhibitor targeting the HCV NS5A protein, which is essential for both RNA replication and the assembly of HCV virions.
Velpatasvir je inhibitor HCV-a usmjeren na NS5A protein HCV-a , koji je neophodan kako za replikaciju RNK, tako i za sklapanje viriona HCV-a.
Velpatasvir is an inhibitor of drug transporter P-gp, breast cancer resistance protein (BCRP), organic anion-transporting polypeptide (OATP) 1B1 and OATP1B3.
Velpatasvir je inhibitor prijenosnika lijeka P-gp-a, proteina rezistencije raka dojke (engl. breast cancer resistance protein, BCRP), polipeptida za prijenos organskih aniona (engl. organic anion transporting polypeptide, OATP) 1B1 i OATP1B3.
Velphoro 500 mg chewable tablets
Velphoro 500 mg tablete za žvakanje
Velphoro 500 mg chewable tablets iron as sucroferric oxyhydroxide
Velphoro 500 mg tablete za žvakanje željezo u obliku saharoželjezovog(III) oksihidroksida
Velphoro contains sucrose and starches (carbohydrates)
Velphoro sadrži saharozu i škrobove (ugljikohidrati)
Velphoro contains sucrose.
Velphoro sadrži saharozu.
Velphoro has been administered to over 245 seniors (≥65 years of age) according to the approved dosing regimen.
Velphoro je primijenjen u više od 245 starijih osoba (≥65 godina starosti), u skladu s odobrenim režimom doziranja.
Velphoro has no or negligible influence on the ability to drive and use machines.
Velphoro ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Velphoro should only be taken by mouth.
Velphoro se smije uzimati samo kroz usta.
Velphoro was as effective as sevelamer in reducing patients’ blood-phosphate levels and maintaining this effect.
Velphoro je bio podjednako djelotvoran kao sevelamer u snižavanju koncentracije fosfata u krvi bolesnika i održavanju ovog djelovanja.
Vemurafenib inhibited CYP2C8 in vitro.
Vemurafenib je inhibirao CYP2C8 in vitro.
Vemurafenib is a moderate CYP1A2 inhibitor.
Vemurafenib je umjeren inhibitor CYP1A2.
Vemurafenib is a substrate and inhibitor of P-gp in vitro.
Vemurafenib je supstrat i inhibitor P-gp in vitro.
Vemurafenib is an inhibitor of BRAF serine-threonine kinase.
Vemurafenib je inhibitor BRAF serin-treonin kinaze.
Vemurafenib may be taken with or without food, but consistent intake of both daily doses on an empty stomach should be avoided (see section 5.2).
Vemurafenib se može uzimati s hranom ili bez nje, no treba izbjegavati konstantno uzimanje obje dnevne doze na prazan želudac (vidjeti dio 5.2).
Vemurafenib may decrease the plasma exposure of substances predominantly metabolised by CYP3A4.
Vemurafenib može smanjiti plazmatsku izloženost lijekovima koji se pretežno metaboliziraju putem CYP3A4.
Vemurafenib may increase the plasma exposure of medicinal products predominantly metabolised by CYP1A2 and decrease the plasma exposure of medicines predominantly metabolised by CYP3A4, including oral contraceptives.
Vemurafenib može povećati izloženost u plazmi lijekova koji se pretežno metaboliziraju putem CYP1A2, a smanjiti izloženost u plazmi lijekova koji se pretežno metaboliziraju putem CYP3A4, uključujući oralne kontraceptive.
Vemurafenib may thus increase the plasma exposure of substances predominantly metabolised by CYP1A2 (e.g. agomelatine, alosetron, duloxetine, melatonin, ramelteon, tacrine, tizanidine, theophylline) and dose adjustments may be considered, if clinically indicated.
Vemurafenib stoga može povećati plazmatsku izloženost lijekova koji se pretežno metaboliziraju putem CYP1A2 (npr. agomelatin, alosetron, duloksetin, melatonin, ramelteon, takrin, tizanidin, teofilin) te se može razmotriti prilagodba doza, ako je to klinički indicirano.
Vemurafenib pharmacokinetics could be affected by medicines that inhibit or influence P-gp (e.g. verapamil, clarithromycin, cyclosporine, ritonavir, quinidine, dronedarone, amiodarone, itraconazole, ranolazine) (see section 4.5).
Na farmakokinetiku vemurafeniba mogu utjecati lijekovi koji inhibiraju ili utječu na P-gp (npr. verapamil, klaritromicin, ciklosporin, ritonavir, kinidin, dronedaron, amiodaron, itrakonazol, ranolazin) (vidjeti dio 4.5).
Vemurafenib should be used with caution in combination with potent inhibitors of CYP3A4, glucuronidation and/or transport proteins (e.g. ritonavir, saquinavir, telithromycin, ketoconazole, itraconazole, voriconazole, posaconazole, nefazodone, atazanavir).
Vemurafenib je potrebno primjenjivati uz oprez u kombinaciji sa snažnim inhibitorima CYP3A4, glukuronidacije i/ili transportnih proteina (npr. ritonavirom, sakvinavirom, telitromicinom, ketokonazolom, itrakonazolom, vorikonazolom, posakonazolom, nefazodonom, atazanavirom).
Vemurafenib treatment can be continued when Cotellic treatment is modified, if clinically indicated.
Ako je klinički indicirano, liječenje vemurafenibom može se nastaviti nakon prilagodbe doze lijeka Cotellic.
Vendel Park, Tormasrét u.
Vendel Park Tormasrét u.
venipuncture set alcohol swabs for single use 2 dry swabs
et za venepunkciju tupfera natopljena alkoholom za jednokratnu primjenu 2 suha tupfera
Venipuncture site haemorrhage
Krvarenje na mjestu uboda u venu
Venlafaxine 50 mg TID (Indinavir 800 mg SD)
Venlafaksin 50 mg TID (indinavir 800 mg SD)
venlafaxine, trazodone - used for depression
venlafaksin, trazodon - koriste se za depresiju
Veno occlusive liver disease *
Vensko-okluzivna bolest jetre
veno-
venookluzivn
Veno-occlusive diseased
Venookluzivna
Veno-occlusive diseased
venookluzivna bolestd
venoocclusive liver disease, hepatic artery thrombosis
venookluzivna bolest jetre, tromboza jetrene arterije
Venous and arterial thromboses3, Hypertension
venska i arterijska tromboza3, hipertenzija
Venous disorder
venski poremećaji
Venous disorder (G3/4: 0.6%)
venski poremećaji (G3/4: 0,6%)
Venous embolic and thrombotic events (see section 4.4)
Venski embolijski i trombotski događaji (vidjeti dio 4.4)
Venous embolic and thrombotic eventsc,d,i
venski embolijski i trombotički događaji c, d,i
Venous occlusive reactions (treatment-emergent frequencies) occurred in 5.0% of patients.
Nuspojave venske okluzije (učestalost nuspojava izazvanih liječenjem) javile su se u 5,0% bolesnika.
Venous thromboembolic event g
venski tromboembolijski događajg
Venous thromboembolic eventd
venski tromboembolijski događajd
Venous thromboembolic events
venski tromboembolijski događaji
Venous thromboembolic events (including, pulmonary embolism, retinal vein thrombosis, deep vein thrombosis and thrombophlebitis)
Venska tromboembolija (uključujući plućnu emboliju, retinalnu vensku trombozu, duboku vensku trombozu i tromboflebitis)
Venous thromboembolic events (VTE) include deep venous thrombosis and pulmonary embolism.
Venski tromboembolijski događaji uključuju duboku vensku trombozu i plućnu emboliju.
Venous thromboembolic events were reported for 1 (1.2%) subject in the sunitinib arm and 5 (6.1%) subjects in the placebo arm in the phase 3 pNET study.
Venski tromboembolijski događaji prijavljeni su u jednog (1,2%) ispitanika u skupini na sunitinibu i u 5 (6,1%) ispitanika u placebo skupini u ispitivanju pNET-a faze III.
Venous thromboembolism (1)
venska tromboembolija (1)
Venous thromboembolism (including deep vein thrombosis, venous thrombosis)
venska tromboembolija (uključujući duboku vensku trombozu, venska tromboza)
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis)
inkopa, venska tromboembolija (uključujući plućnu emboliju i duboku vensku trombozu)
Venous thromboembolism (including pulmonary embolism and deep vein thrombosis) Hypertension
venska tromboembolija (uključujući plućnu emboliju i
Venous thromboembolism - current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]).
Venska tromboembolija – trenutno prisutna VTE (na antikoagulansima) ili VTE u anamnezi (npr. duboka venska tromboza [DVT] ili plućna embolija [PE]).
Venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone in newly diagnosed multiple myeloma and with monotherapy in myelodysplastic syndromes.
Venska tromboembolija opažena je u manjem opsegu u kombinaciji lenalidomida s melfalanom i prednizonom kod novodijagnosticiranog multiplog mijeloma te kod monoterapije kod mijelodisplastičnih sindroma.
Venous thromboembolism was seen to a lesser extent with lenalidomide in combination with melphalan and prednisone in newly diagnosed multiple myeloma.
Venska tromboembolija opažena je u manjem opsegu u kombinaciji lenalidomida s melfalanom i prednizonom kod novodijagnosticiranog multiplog mijeloma.
Venous thromboembolism – current VTE (on anticoagulants) or history of (e.g. deep venous thrombosis [DVT] or pulmonary embolism [PE]);
Venska tromboembolija – prisutna VTE (na antikoagulansima) ili VTE u povijesti bolesti (npr. duboka venska tromboza [DVT] ili plućna embolija [PE]).
Venous thromboembolism, Hypertension
venska tromboembolija, hipertenzija
venous thromboembolism, including thrombophlebitis, venous thrombosis and pulmonary embolism
venska tromboembolija, uključujući tromboflebitis, vensku trombozu i plućnu emboliju
Venous thrombosis (including deep vein thrombosis)
venska tromboza (uključujući duboku vensku trombozu)
venous thrombosis deep limb, shock, infarction
ishemijska bolest
venous thrombosis deep limb, shock, infarction
tromboza dubokih vena ekstremiteta, šok, infarkt
Venous thrombosis limb
Venska tromboza uda
Venous thrombosis**†
venska tromboza
venous thrombosis, arterial thrombosis, thrombophlebitis, arterial stenosis, intermittent claudication, flushing
venska tromboza, arterijska tromboza, tromboflebitis, arterijska stenoza, intermitentna klaudikacija, crvenilo
venous thrombosis, flushing
crvenilo uz
Venous thrombosis, phlebitis, venous burning, hot flush
venska tromboza, flebitis, žarenje vena, navale vrućine
Venous thrombosis/thromboembolism
venska tromboza/tromboembolija
vent
aj
Venta-Neb nebuliser (2 ml ampoule with white and pink rings)
Atomizator Venta-Neb (ampula od 2 ml s bijelim i ružičastim prstenom)
Venta-Neb, a portable ultrasonic battery-powered nebuliser, has also been shown to be suitable for the administration of Ventavis 10 microgram/ml.
Venta-Neb, prijenosni ultrazvučni atomizator s baterijskim napajanjem pokazao se prikladnim za primjenu lijeka Ventavis 10 mikrograma/ml.
Venta-Neb, a portable ultrasonic battery-powered nebuliser, has been shown to be suitable for the administration of Ventavis 10 microgram/ml nebuliser solution (2 ml ampoule).
Venta-Neb, prijenosni ultrazvučni atomizator s baterijskim napajanjem pokazao se prikladnim za primjenu Ventavis 10 mikrograma/ml otopine za atomizator (ampula od 2 ml).
Ventavis 10 mcg/ml
Ventavis 10 mikrograma/ml
Ventavis 10 mcg/ml
Ventavis 10 µg/ml
Ventavis 10 microgram/ml
Ventavis 10 mikrograma/ml
Ventavis 10 microgram/ml (1 ml ampoule) and Ventavis 20 microgram/ml nebuliser solution
Ventavis 10 mikrograma/ml (ampula od 1 ml) i Ventavis 20 mikrograma/ml otopina za atomizator
Ventavis 10 microgram/ml is provided in colourless ampoules, containing either 1 ml or 2 ml nebuliser solution.
Ventavis 10 mikrograma/ml je dostupan u bezbojnim ampulama koje sadrže ili 1 ml ili 2 ml otopine za atomizator.
Ventavis 10 microgram/ml nebuliser solution
Ventavis 10 mikrograma/ml otopina za atomizator
Ventavis 10 microgram/ml nebuliser solution (1 ml ampoule)
Ventavis 10 mikrograma/ml otopina za atomizator (ampula od 1 ml)
Ventavis 10 microgram/ml nebuliser solution (1 ml ampoule) delivers 2.5 microgram and Ventavis 20 microgram/ml nebuliser solution delivers 5 microgram at the mouthpiece of the Breelib nebuliser.
Ventavis 10 mikrograma/ml (ampula od 1 ml) otopina za atomizator isporučuje 2,5 mikrograma, a Ventavis 20 mikrograma/ml otopina za atomizator isporučuje 5 mikrograma u nastavku za usta Breelib atomizatora.
Ventavis 10 microgram/ml nebuliser solution 2 years.
Ventavis 10 mikrograma/ml otopina za atomizator 2 godine.
Ventavis 10 microgram/ml nebuliser solution Clear, colourless solution.
Ventavis 10 mikrograma/ml otopina za atomizator Bistra, bezbojna otopina.
Ventavis 10 microgram/ml nebuliser solution Iloprost
Ventavis 10 mikrograma/ml otopina za atomizator iloprost
Ventavis 10 microgram/ml nebuliser solution is inhaled using the nebulisers your doctor prescribed (either the Breelib, the Venta-Neb or the I-Neb AAD system).
Ventavis 10 mikrograma/ml otopina za atomizator inhalira se pomoću atomizatora kojeg Vam je propisao liječnik (sustav Breelib, Venta-Neb ili I-Neb AAD).
Ventavis 10 microgram/ml nebuliser solution Ventavis 20 microgram/ml nebuliser solution
Ventavis 10 mikrograma/ml otopina za atomizator Ventavis 20 mikrograma/ml otopina za atomizator
Ventavis 10 microgram/ml, Nebuliser solution Iloprost
Ventavis 10 mikrograma/ml otopina za atomizator iloprost
Ventavis 10 microgram/ml:
Ventavis 10 mikrograma/ml:
Ventavis 20 mcg/ml
Ventavis 20 mikrograma/ml
Ventavis 20 mcg/ml
Ventavis 20 µg/ml
Ventavis 20 microgram/ml
Ventavis 20 mikrograma/ml
Ventavis 20 microgram/ml is available in the following packs:
Ventavis 20 mikrograma/ml je dostupan u sljedećim pakiranjima:
Ventavis 20 microgram/ml is provided in colourless ampoules, containing 1 ml nebuliser solution.
Ventavis 20 mikrograma/ml je dostupan u bezbojnim ampulama koje sadrže 1 ml otopine za atomizator.
Ventavis 20 microgram/ml nebuliser solution
Ventavis 20 mikrograma/ml otopina za atomizator
Ventavis 20 microgram/ml nebuliser solution 5 years.
Ventavis 20 mikrograma/ml otopina za atomizator 5 godina.
Ventavis 20 microgram/ml nebuliser solution Clear, colourless to slightly yellowish solution.
Ventavis 20 mikrograma/ml otopina za atomizator Bistra, bezbojna do blago žućkasta otopina.
Ventavis 20 microgram/ml nebuliser solution Iloprost
Ventavis 20 mikrograma/ml otopina za atomizator iloprost
Ventavis 20 microgram/ml nebuliser solution is inhaled using the nebulisers your doctor prescribed (either the Breelib or the I-Neb AAD nebuliser).
Ventavis 20 mikrograma/ml otopina za atomizator inhalira se pomoću atomizatora kojeg Vam je propisao liječnik (Breelib ili I-Neb AAD atomizator).
Ventavis 20 microgram/ml:
Ventavis 20 mikrograma/ml:
Ventavis has major influence on the ability to drive and use machines for patients experiencing hypotensive symptoms such as dizziness.
U bolesnika sa simptomima hipotenzije, primjerice omaglicom, Ventavis značajno utječe na sposobnost upravljanja vozilima i rada sa strojevima.
Ventavis is a clear, colourless nebuliser solution for inhalation with the Breelib, the I-Neb or the Venta-Neb nebuliser.
Ventavis je bistra, bezbojna otopina za atomizator namijenjena za inhalaciju pomoću atomizatora Breelib, I-Neb ili Venta-Neb.
Ventavis is a clear, colourless to slightly yellowish nebuliser solution for inhalation with the Breelib or the I-Neb nebuliser.
Ventavis je bistra, bezbojna do blago žućkasta otopina za atomizator namijenjena za inhalaciju pomoću Breelib ili I-Neb atomizatora.
Ventavis nebuliser solution should not come into contact with skin and eyes; oral ingestion of Ventavis solution should be avoided.
Ventavis otopina za atomizator ne smije doći u kontakt s kožom ni očima; mora se izbjeći ingestija otopine Ventavis.
Ventilation support
Ventilacijska potpora
Ventricular
dizartrija
Ventricular
fibrilacija
Ventricular
Ventrikularna
Ventricular arrhythmia
ventrikularna aritmija
Ventricular arrhythmia*,
Nazalna kongestija
Ventricular arrhythmias (including ventricular tachycardia, torsade de pointes) have been reported in patients treated with telithromycin and sometimes occurred within a few hours of the first dose (see section 4.8).
Ventrikularne artimije (uključujući ventrikularnu tahikardiju, torsades de pointes) prijavljene su u bolesnika liječenih telitromicinom i ponekad su se pojavile unutar nekoliko sati od prve doze (vidjeti dio 4.8).